Clinical Trials Browser

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05926024 2026-03-11

Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment

Active not recruiting

253 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT07066189 2025-10-29

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC

Phase NA Recruiting

160 enrolled

Breast

Pathologic Complete Response, Motor Activity, Triple Negative Breast Neoplasms

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Phase 3 Active not recruiting

325 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07164872 2025-09-10

Neoadjuvant Chemotherapy Combined With Preoperative Radiotherapy for Locally Advanced Breast Cancer

Phase NA Not yet recruiting

50 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT07166185 2025-09-10

NEOTRAPSCAL

Recruiting

70 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT05416164 2025-03-26

DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy

Phase NA Recruiting

595 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT05976815 2025-03-26

KEYMOVE

Phase NA Recruiting

86 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms, Motor Activity

NCT05350722 2024-12-30

ABLATIVE-2

Phase NA Recruiting

100 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT05659056 2024-04-16

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

Phase 2 Recruiting

65 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT05103293 2023-12-27

PTC Guiding Neoadjuvant Treatment in Breast Cancer

Phase 2 Completed

86 enrolled

BreastOther neoplasm

Pathologic Complete Response, Breast Neoplasms, Pathological Conditions, Signs and Symptoms

NCT05371860 2023-09-22

Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response

Phase 2 Withdrawn

Breast

Pathologic Complete Response, Breast Neoplasms

NCT05763992 2023-05-18

BREAKFAST-2

Phase 2 Recruiting

145 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms, Fasting, Triple Negative Breast Neoplasms

NCT04457700 2022-04-18

CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC

Unknown

218 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04781725 2021-11-17

INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer

Phase 2 Unknown

90 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT05050890 2021-09-30

GIRO_ctDNA

Unknown

38 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT02511847 2016-04-15

Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib

Phase 2 Unknown

40 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00636441 2015-12-11

Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer

Phase 2 Terminated

56 enrolled 16 charts

Breast

Pathologic Complete Response, Breast Neoplasms

NCT02613026 2015-11-24

Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer

Phase 3 Completed

104 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT02059876 2014-02-12

Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer

Phase 2 Unknown

60 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT01956513 2013-10-08

ADC

Phase NA Withdrawn

Breast

Pathologic Complete Response, Breast Neoplasms

NCT01433926 2011-09-14

LongHer

Completed

114 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT01203267 2010-09-16

Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer

Phase 2 Completed

108 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

Clinical Trials

I-SPY

Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Neoadjuvant Chemotherapy Combined With Preoperative Radiotherapy for Locally Advanced Breast Cancer

NEOTRAPSCAL

DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy

KEYMOVE

ABLATIVE-2

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

PTC Guiding Neoadjuvant Treatment in Breast Cancer

Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response

BREAKFAST-2

CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC

INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer

GIRO_ctDNA

Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib

Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer

Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer

Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer

ADC

LongHer

Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer